Cargando…
Addition of dexmedetomidine to benzodiazepines for patients with alcohol withdrawal syndrome in the intensive care unit: a randomized controlled study
BACKGROUND: Dexmedetomidine (DEX) is a centrally acting alpha-2-adrenoceptor agonist that has potential in the management of alcohol withdrawal syndrome (AWS) owing to its ability to produce arousable sedation and to inhibit the adrenergic system without respiratory depression. The objective of this...
Autores principales: | Bielka, Kateryna, Kuchyn, Iurii, Glumcher, Felix |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Paris
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630264/ https://www.ncbi.nlm.nih.gov/pubmed/26525052 http://dx.doi.org/10.1186/s13613-015-0075-7 |
Ejemplares similares
-
Dexmedetomidine infusion as an analgesic adjuvant during laparoscopic сholecystectomy: a randomized controlled study
por: Bielka, Kateryna, et al.
Publicado: (2018) -
Psoas compartment block efficacy and safety for perioperative analgesia in the elderly with proximal femur fractures: a randomized controlled study
por: Bielka, Kateryna, et al.
Publicado: (2021) -
Patient safety during anesthesia in Ukraine: national audit results
por: Bielka, Kateryna, et al.
Publicado: (2022) -
Association between dexmedetomidine use for the treatment of alcohol withdrawal syndrome and intensive care unit length of stay
por: Yavarovich, Ekaterina R., et al.
Publicado: (2019) -
Catatonia in mixed alcohol and benzodiazepine withdrawal
por: Basu, Aniruddha, et al.
Publicado: (2014)